Johnson & Johnson (JNJ) Long-Term Debt Repayments (2009 - 2024)
Johnson & Johnson's (JNJ) quarterly Long-Term Debt Repayments came in at $1.0 million in Q1 2024, down 99.8% year-over-year from $500.0 million in Q2 2023, and down 99.9% quarter-over-quarter from $1.0 billion in Q4 2023.
Analysis
Johnson & Johnson (JNJ) Long-Term Debt Repayments (2009 - 2024) Analysis & Trends
Johnson & Johnson has disclosed Long-Term Debt Repayments across 16 years of filings, most recently posting $1.0 million for Q1 2024.
- In Q1 2024, Long-Term Debt Repayments fell 99.8% year-over-year to $1.0 million; the TTM figure through Mar 2024 stood at $1.1 billion (down 68.27% YoY), while the FY2025 annual figure was $1.8 billion, up 20.92% from the prior year.
- Long-Term Debt Repayments came in at $1.0 million for Q1 2024 at Johnson & Johnson, down from $1.0 billion in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $2.1 billion in Q2 2022 to a low of $1.0 million in Q4 2021.
- Average Long-Term Debt Repayments over 5 years is $529.4 million, with a median of $500.0 million recorded in 2023.
- Year-over-year, Long-Term Debt Repayments surged 18266.67% in 2020 and sank 99.82% in 2021.
- Over 5 years, Long-Term Debt Repayments stood at $551.0 million in 2020, then slumped by 99.82% to $1.0 million in 2021, then soared by 213100.0% to $2.1 billion in 2022, then tumbled by 50.8% to $1.0 billion in 2023, then slumped by 99.9% to $1.0 million in 2024.
- Per Business Quant data, the three most recent Long-Term Debt Repayments figures were $1.0 million in Q1 2024, $1.0 billion in Q4 2023, and $1.0 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 2.00 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 5.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 17.05 Mn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 1.00 Mn |
| Dec 31, 2023 | 1.05 Bn |
| Oct 1, 2023 | 1.00 Mn |
| Jul 2, 2023 | 1.00 Mn |
| Apr 2, 2023 | 500.00 Mn |
| Jan 1, 2023 | 682.00 Mn |
| Apr 3, 2022 | 2.13 Bn |
| Oct 3, 2021 | 1.00 Mn |
| Jul 4, 2021 | 450.00 Mn |
| Apr 4, 2021 | 1.00 Bn |
| Jan 3, 2021 | 502.00 Mn |
| Sep 27, 2020 | 551.00 Mn |
| Mar 29, 2020 | 11.00 Mn |
| Dec 29, 2019 | 1.82 Bn |
| Sep 29, 2019 | 3.00 Mn |
| Jun 30, 2019 | 3.00 Mn |
| Mar 31, 2019 | 1.00 Bn |
| Dec 30, 2018 | 645.00 Mn |
| Sep 30, 2018 | 901.00 Mn |
| Jul 1, 2018 | 1.00 Mn |